Clinical Trial Update: Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial evaluating sorafenib to prevent leukemia relapse after allogeneic stem cell transplantation in FLT3-ITD positive AML; completed phases 2 and 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Hematopoietic Stem Cell Transplantation

Drugs mentioned

• Sorafenib (Sorafenib)

Snippet

Sponsor: Nanfang Hospital, Southern Medical University | Conditions: Acute Myeloid Leukemia, Hematopoietic Stem Cell Transplantation | Phase 2, Phase 3 | Status: COMPLETED